[{"id":"d2eab13c-3e7c-4257-8119-cdbb100f01e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05483530","created_at":"2022-08-02T13:55:16.496Z","updated_at":"2024-07-02T16:35:09.508Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05483530","lead_sponsor":"Shanghai Henlius Biotech","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hetronifly (serplulimab) • HLX60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/14/2022","start_date":" 12/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-16"}]